
GenBank Accession No.: Submission in progress.

Sold as part of Cat. No. 634401



Restriction Map and Multiple Cloning Site (MCS) of pMSCVneo. All restriction sites shown are unique.

Description

The Murine Stem Cell Virus (MSCV) vectors were derived from the Murine Embryonic Stem Cell Virus (MESV) and the LN retroviral vectors (1,2). Upon transfection into a packaging cell line, pMSCVneo transiently expresses, or integrates and stably expresses, a transcript containing the extended viral packaging signal Ψ⁺, the neomycin resistance gene, and a gene of interest. The vectors achieve stable, high-level gene expression in hematopoietic and embryonic stem cells through a specifically designed 5' long terminal repeat (LTR). This LTR is from the murine stem cell PCMV virus, and it differs from the MoMuLV LTR used in other retroviral vectors by several point mutations and a deletion. These changes enhance transcriptional activation and prevent transcriptional suppression in embryonic stem and embryonal carcinoma cells. As a result, the LTR drives high-level constitutive expression of a target gene in stem cells or other mammalian cell lines (3). A gene can be cloned into the multiple cloning site immediately downstream of this LTR. The murine phosphoglycerate kinase (PKG) promoter (P_{PKG}) controls expression of the neomycin resistance gene (Neo^r) for antibiotic selection in eukaryotic cells. pMSCVneo also contains the pUC origin of replication and E. coli Amp^r gene for propagation and antibiotic selection in bacteria.

Use

pMSCVneo can be transfected into a packaging cell line such as the RetroPack™ PT67 Cell Line (Cat. No. 631510). Once in the cell, RNA from the vector is packaged into infectious, replicationincompetent retroviral particles. pMSCVneo does not contain the gag, pol, and env structural genes necessary for particle formation and replication: these genes are stably integrated into the PT67 genome (4-7). Introduction of pMSCVneo into a packaging cell line results in production of hightiter, replication-incompetent infectious virus particles. These particles can infect target cells and transmit the gene of interest to them. However, they cannot replicate because the target cells lack viral structural genes. The process of separately introducing and integrating the structural genes into the packaging cell line minimizes the chances of producing replication-competent virus due to recombination events during cell proliferation.



United States/Canada 800.662.2566

Asia Pacific +1.650.919.7300

Europe +33.(0)1.3904.6880

Japan +81.(0)77.543.6116

Clontech Laboratories, Inc. ATakara Bio Company

1290 Terra Bella Ave. Mountain View, CA 94043 Technical Support (US) E-mail: tech@clontech.com www.clontech.com

(PR37257; published 23 July 2003)

pMSCVneo **Vector Information**

Location of features:

5' PCMV LTR: 1–515

 Ψ⁺ (extended packaging signal): 516–1405 Neomycin resistance gene (Neo^r): 1951–2751

PKG promoter: 1429–1937

Multiple Cloning Site: 1406–1429

 3' PCMV LTR: 2859–3342 · Col E1origin of replication:

Site of replication initiation: 3913

Ampicillin resistance gene (β-lactamase): 5533–4676

Sequencing primer locations:

• pMSCV Primers:

5' primer (1333–1355): 5'-CCCTTGAACCTCCTCGTTCGACC-3' 3' primer (1660-1682): 5'-GAGACGTGCTACTTCCATTTGTC-3'

Propagation in E. coli:

Suitable host strains: DH5α, HB101, and other general purpose strains.

Selectable marker: plasmid confers resistance to ampicillin (50 μg/ml) to E. coli hosts.

• E. coli replication origin: Col E1

· Copy number: low

Note: The viral supernatants produced by this retroviral vector could, depending on your cloned insert, contain potentially hazardous recombinant virus. Due caution must be exercised in the production and handling of recombinant retrovirus. Appropriate NIH, regional, and institutional guidelines apply.

References:

- 1. Grez, M., et al. (1990) Proc. Natl. Acad. Sci. USA 87:9202-9206.
- Miller, A. D. & Rosman, G. J. (1989) BioTechniques 7:980-990.
- Hawley, T.S. et al. (1994) Gene Ther. 1:136-138.
- Mann, R., et al. (1983) Cell 33:153-159.
- Miller, A. D. & Buttimore, C. (1986) Mol. Cell. Biol. 6:2895-2902.
- Morgenstern, J. P. & Land, H. (1990) Nucleic Acids Res. 18:3587-3590.
- Miller, A. D. & Chen, F. (1996) J. Virol. 70:5564-5571.

Notice to Purchaser

This product is intended to be used for research purposes only. It is not to be used for drug or diagnostic purposes, nor is it intended for human use. Clontech products may not be resold, modified for resale, or used to manufacture commercial products without written approval of Clontech

The RetroPack™ PT67 Cell Line is covered under U.S. Patent No. 5,766,945, which has been assigned to the Fred Hutchinson Cancer Research Center. Rights to use this product are limited to research only. No other rights are conveyed. Inquiry into the availability of a license to broader rights or the use of this product for commercial purposes should be directed to Fred Hutchinson Cancer Research Center, Technology Transfer Office, 1100 Fairview Avenue North, J6-200, Seattle, WA 98109. Purchase of this product does not grant rights to: (1) offer the materials or any derivatives thereof for resale; or (2) to distribute or transfer the materials or any derivatives thereof to third parties.

Use of the MSCV Retroviral Expression System is exclusively licensed from Robert G. Hawley, Ph.D. Academic research institutions are granted an automatic license with the purchase of this product to use the MSCV Retroviral Expression System only for internal, academic research purposes. This limitation expressly excludes the right to sell or otherwise transfer the MSCV system or its component parts to third parties. All other users and purchasers are required to obtain a license from Clontech prior to purchasing these reagents or using them for any purpose. For information on licensing please contact a licensing representative by phone at 650.919.7320 or by e-mail at licensing@clontech.com

Clontech, Clontech logo and all other trademarks are the property of Clontech Laboratories, Inc. Clontech is a Takara Bio Company. ©2005

Clontech Laboratories, Inc. Protocol No. PT3301-5 www.clontech.com Version No. PR37257